Search Results
54 results
Your search is now limited to «Biosimilars» expert search.
Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology.
More from Global Banking & Finance Review:
Zacks.com 01/30/2019 08:46
Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.
More from Zacks.com:
Company Drug/Device Medical Condition Status Ironwood Pharmaceuticals IW-6463 serious and orphan Central Nervous System (CNS) disorders Phase I trial initiated enrolling healthy volunteer subjects Concert Pharmaceuticals CTP-692 adjunctive treatment for schizophrenia Phase I trial initiated Curis, Inc. CA-170 (oral dual inhibitor of VISTA and PDL1) mesothelioma Phase I trial initiated Second Genome, Inc. SGM-1019 nonalcoholic [...]
Business Wire 01/29/2019 06:45
Pfizer also incorporated its biosimilar portfolio into its Oncology and Inflammation & Immunology business units.
More from Business Wire:
PharmaBiz.com 01/28/2019 05:36
Amgen and Allergan announced positive top─line results from a phase 1/ phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to Rituxan.
More from PharmaBiz.com:
pharmaphorum 01/28/2019 04:08
AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly in Europe – weakened cash cow product Humira. Revenues from the immunology blockbuster grew 1% to $4.9 bill...
More from pharmaphorum:
NASDAQ 01/27/2019 20:43
AbbVie NYSE ABBV investors have been dreading this moment since the company s inception in 2013 International Humira sales tumbled during the fourth quarter following the loss of patent protected market exclusivity Sales of the world s top selling drug probably peaked 2018.
More from NASDAQ:
Amgen News Release 01/24/2019 09:01
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis. THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokinetic (PK) similarity. Additionally, equivalent efficacy was established and a similar...
CreakyJoints 01/23/2019 07:45
This news about biosimilar switching safety could alleviate patient concerns. The post Want to Switch Back to a Biologic IBD Drug After Taking a Biosimilar? New Study Says It’s Safe appeared first on CreakyJoints .
More from CreakyJoints:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications